{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:31:19Z","timestamp":1765279879368},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T00:00:00Z","timestamp":1418774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00404-014-3590-0","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T07:21:53Z","timestamp":1418714513000},"page":"1381-1386","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma"],"prefix":"10.1007","volume":"291","author":[{"given":"Mark A.","family":"Rettenmaier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto A.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa N.","family":"Abaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"John V.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Micha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber M.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram H.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"3590_CR1","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.2174\/138161212802002616","volume":"18","author":"S Mulier","year":"2012","unstructured":"Mulier S, Claes JP, Dierieck V et al (2012) Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des 18:3793\u20133803","journal-title":"Curr Pharm Des"},{"key":"3590_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4251\/wjgo.v2.i1.31","volume":"2","author":"E Cotte","year":"2010","unstructured":"Cotte E, Passot G, Gilly FN et al (2010) Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2:31\u201335","journal-title":"World J Gastrointest Oncol"},{"key":"3590_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ygyno.2013.01.010","volume":"129","author":"PA Argenta","year":"2013","unstructured":"Argenta PA, Sueblinvong T, Geller MA et al (2013) Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol 129:81\u201385","journal-title":"Gynecol Oncol"},{"key":"3590_CR4","doi-asserted-by":"publisher","first-page":"e81858","DOI":"10.1371\/journal.pone.0081858","volume":"8","author":"M Zhou","year":"2013","unstructured":"Zhou M, Yu P, Qu X et al (2013) Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One 8:e81858","journal-title":"PLoS One"},{"key":"3590_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"3590_CR6","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"3590_CR7","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3\u00a0months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460\u20132465","journal-title":"J Clin Oncol"},{"key":"3590_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34\u201343","journal-title":"N Engl J Med"},{"key":"3590_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/ejso.2000.0978","volume":"26","author":"N Vange van der","year":"2000","unstructured":"van der Vange N, van Goethem AR, Zoetmulder FA (2000) Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 26:663\u2013668","journal-title":"Eur J Surg Oncol"},{"key":"3590_CR10","first-page":"121","volume":"13","author":"Y Yoshida","year":"2005","unstructured":"Yoshida Y, Sasaki H, Kurokawa T et al (2005) Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up. Oncol Rep 13:121\u2013125","journal-title":"Oncol Rep"},{"key":"3590_CR11","first-page":"369","volume":"22","author":"B Salle","year":"1993","unstructured":"Salle B, Gilly FN, Carry PY et al (1993) Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data. J Gynecol Obstet Biol Reprod 22:369\u2013371","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"3590_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/or.2013.2473","volume":"30","author":"V Francescutti","year":"2013","unstructured":"Francescutti V, Rivera L, Seshadri M et al (2013) The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. Oncol Rep 30:35\u201342","journal-title":"Oncol Rep"},{"key":"3590_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3109\/02656736.2014.952251","volume":"30","author":"A Arjona-Sanchez","year":"2014","unstructured":"Arjona-Sanchez A, Mu\u00f1oz-Casares C, Ortega-Salas R et al (2014) Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 30:408\u2013411","journal-title":"Int J Hyperthermia"},{"key":"3590_CR14","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s11605-014-2477-5","volume":"18","author":"P Tabrizian","year":"2014","unstructured":"Tabrizian P, Shrager B, Jibara G et al (2014) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg 18:1024\u20131031","journal-title":"J Gastrointest Surg"},{"key":"3590_CR15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","volume":"22","author":"L Ansaloni","year":"2012","unstructured":"Ansaloni L, Agnoletti V, Amadori A et al (2012) Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22:778\u2013785","journal-title":"Int J Gynecol Cancer"},{"key":"3590_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1525-1438.2005.15209.x","volume":"15","author":"J Gori","year":"2005","unstructured":"Gori J, Casta\u00f1o R, Toziano M et al (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15:233\u2013239","journal-title":"Int J Gynecol Cancer"},{"key":"3590_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1245\/s10434-008-0299-y","volume":"16","author":"MC Lim","year":"2009","unstructured":"Lim MC, Kang S, Choi J et al (2009) Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol 16:993\u20131000","journal-title":"Ann Surg Oncol"},{"key":"3590_CR18","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1245\/s10434-007-9463-z","volume":"14","author":"SJ Lim","year":"2007","unstructured":"Lim SJ, Cormier JN, Feig BW et al (2007) Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol 14:2309\u20132318","journal-title":"Ann Surg Oncol"},{"key":"3590_CR19","doi-asserted-by":"publisher","first-page":"307317","DOI":"10.1155\/2014\/307317","volume":"2014","author":"HN L\u00f3pez-Basave","year":"2014","unstructured":"L\u00f3pez-Basave HN, Morales-Vasquez F, Mendez-Herrera C et al (2014) Intensive care unit admission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Is it necessary? J Oncol 2014:307317","journal-title":"J Oncol"},{"key":"3590_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ygyno.2007.03.022","volume":"106","author":"SS Lentz","year":"2007","unstructured":"Lentz SS, Miller BE, Kucera GL et al (2007) Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol 106:207\u2013210","journal-title":"Gynecol Oncol"},{"key":"3590_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","volume":"94","author":"KS Ryu","year":"2004","unstructured":"Ryu KS, Kim JH, Ko HS et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94:325\u2013332","journal-title":"Gynecol Oncol"},{"key":"3590_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63\u201368","journal-title":"J Clin Oncol"},{"key":"3590_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1006\/gyno.1998.5145","volume":"72","author":"RE Bristow","year":"1999","unstructured":"Bristow RE, Montz FJ, Lagasse LD et al (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278\u2013287","journal-title":"Gynecol Oncol"},{"key":"3590_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"3590_CR25","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","volume":"19","author":"GJ Rustin","year":"2001","unstructured":"Rustin GJ, Marples M, Nelstrop AE (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054\u20134057","journal-title":"J Clin Oncol"},{"key":"3590_CR26","volume-title":"Common terminology criteria for adverse events (version 4.03)","author":"NIH","year":"2010","unstructured":"NIH (2010) Common terminology criteria for adverse events (version 4.03). National Institute of Health, Washington"},{"key":"3590_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jmig.2009.07.019","volume":"16","author":"MA Rettenmaier","year":"2009","unstructured":"Rettenmaier MA, Abaid LN, Erwin MR et al (2009) A retrospective review of the GelPort system in single-port access pelvic surgery. J Minim Invasive Gynecol 16:743\u2013747","journal-title":"J Minim Invasive Gynecol"},{"key":"3590_CR28","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gunbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"3590_CR29","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"3590_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskin WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC. N Engl J Med 334:1\u20136","journal-title":"N Engl J Med"},{"key":"3590_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/bjc.1994.45","volume":"69","author":"G Los","year":"1994","unstructured":"Los G, van Vugt MJ, Pinedo HM (1994) Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235\u2013241","journal-title":"Br J Cancer"},{"key":"3590_CR32","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/IGC.0b013e3181e94331","volume":"20","author":"JV Brown 3rd","year":"2010","unstructured":"Brown JV 3rd, Micha JP, Rettenmaier MA et al (2010) A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer 20:1132\u20131136","journal-title":"Int J Gynecol Cancer"},{"key":"3590_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Y Miyagi","year":"2005","unstructured":"Miyagi Y, Fujiwara K, Kigawa J et al (2005) Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin\u2014a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 99:591\u2013596","journal-title":"Gynecol Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-014-3590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-014-3590-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-014-3590-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-014-3590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T22:40:38Z","timestamp":1581979238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-014-3590-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3590"],"URL":"https:\/\/doi.org\/10.1007\/s00404-014-3590-0","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]},"assertion":[{"value":"17 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}